The initial success of Sildenafil undeniably transformed the drug landscape, but betting in companies primarily reliant on generic versions presents a uncertain picture. While early returns were impressive, the cessation of patents and the rise of less expensive alternatives have eroded the customer base. Consequently, a thorough analysis of presen